Glutamate ionotropic receptor NMDA type subunit (NMDA receptor subunit (commonly abbreviated as GluN1, GluN2A-D, or GluN3A-B depending on the specific gene product)[1][4][7])

The **glutamate ionotropic receptor NMDA type subunit** refers to one of several protein components that assemble to form functional **NMDA receptors**, a subclass of ligand-gated ion channels activated by glutamate. These receptors are heterotetramers typically composed of two obligatory **GluN1** subunits encoded by *GRIN1*, combined with two regulatory **GluN2** (*GRIN2A-D*) or sometimes **GluN3** (*GRIN3A-B*) subunits. The precise combination determines pharmacological properties and physiological roles. Located primarily at postsynaptic sites in neurons throughout the central nervous system, these receptors mediate calcium influx upon activation by glutamate and glycine co-binding. This activity is essential for synaptic plasticity processes such as long-term potentiation—key mechanisms underlying learning and memory. NMDA-type glutamate receptors are implicated in numerous neurological diseases due to their central role in excitatory neurotransmission; both overactivation ("excitotoxicity") and underactivity can contribute to pathology. They are established drug targets for conditions including depression, neurodegeneration, stroke recovery, chronic pain syndromes, anesthesia induction/dissociation states—and remain an area of active research for novel therapeutics.[1][4][6][7]

Other names

NMDA receptor subunitNMDAR subunitNR1 (for GluN1)NR2A, NR2B, NR2C, NR2D (for GluN2A-D)NR3A, NR3B (for GluN3A-B)GRIN1/GRIN2/GRIN3 gene products[1][4][7]

Drugs targeting this molecule act via several mechanisms including: - Noncompetitive antagonism of the ion channel pore (e.g., ketamine blocks open channels) [5] - Uncompetitive antagonism at the Mg²⁺ binding site within the channel pore [8][5] - Competitive inhibition at glutamate or glycine binding sites on specific subunits [4][7]